0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 21, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the Deutsche Bank 38th Annual
dbAccess Health Care Conference on Wednesday, May 29, 2013 at 2:50 p.m.
ET at The Westin Boston Waterfront Hotel in... Contine Reading & Discuss→
0 Replies
– RNAi Therapeutics Targeting ALAS-1 Completely Block Production of
Toxic Heme Biosynthesis Intermediates that Cause Symptoms and Disease
Pathology –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 17, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that it has presented
key pre-clinical proof-of-concept data from its RNAi therapeutic program... Contine Reading & Discuss→
0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 15, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 2013 UBS Global Healthcare Conference on Wednesday, May 22, 2013
at 8:00 a.m. ET at The Sheraton New York Hotel in New York City.... Contine Reading & Discuss→
0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 8, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the 2013 Bank of America Merrill Lynch
Health Care Conference on Thursday, May 16, 2013 at 8:40 a.m. PT (11:40
a.m. ET) at Encore at... Contine Reading & Discuss→
0 Replies
– Continued to Execute on “Alnylam 5x15” Product Strategy,
Positioning Company for Data-Rich Period over Next Several Months –
– Formed Strategic Alliance with The Medicines Company to Develop and
Commercialize ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the
Treatment of Hypercholesterolemia –
– Completed Successful Public Offering of Stock;... Contine Reading & Discuss→
0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that it will report
financial results for the first quarter ending March 31, 2013 on Monday,
May 6, 2013, after the U.S. financial markets close.
Management will provide an update on the company,... Contine Reading & Discuss→
0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 23, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 12th Annual Needham Healthcare Conference on Tuesday,
April 30, 2013 at 3:40 p.m. ET at the Westin Grand Central Hotel in New
York City.... Contine Reading & Discuss→
0 Replies
– ALN-TTRsc is Company’s First Subcutaneously Delivered RNAi
Therapeutic to Enter Clinical Trials –
– Data from Trial Expected Mid-2013 –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 18, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it has initiated dosing in its Phase I
clinical trial with... Contine Reading & Discuss→
0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the Barclays Global Healthcare Conference on Tuesday, March 12, 2013
at 10:15 a.m. ET at the Loews Miami Hotel in Miami, Florida.
A live audio... Contine Reading & Discuss→
0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the Cowen and Company 33rd
Annual Health Care Conference on Tuesday, March 5, 2013 at 8:40 a.m. ET
at the Boston Marriott Copley Place.
A... Contine Reading & Discuss→
